Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fasudil vs clazosentan for prevention of cerebral vasospasm after aneurysmal subarachnoid hemorrhage
jRCT1041240128Recruiting
- Sponsor
- Nagoya University Hospital
- Start
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised trial in subarachnoid hemorrhage (SAH) and cerebral vasospasm comparing Fasudil with Clazosentan (2 arms). Primary endpoint: modified Rankin Scale (mRS) at 90 days after onset. Started Mar 2025; status: recruiting.
02
Drugs
fasudilclazosentan
03
Conditions
subarachnoid hemorrhage (SAH)cerebral vasospasm
Beyond the preview
Go deeper on jRCT1041240128.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1041240128.